Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Oncogene|September 20, 2017
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistanceS Ramadoss, S Sen, I Ramachandran, et al.Oncogene|October 4, 2016
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistanceS Ramadoss, S Sen, I Ramachandran, et al.Neurochemical Research|July 25, 2000
Searching for depolarization-induced genes that modulate synaptic plasticity and neurotrophin-induced genes that mediate neuronal differentiationH R Herschman, G D Ferguson, J D Feldman, et al.The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 11, 2000
The urokinase plasminogen activator receptor (UPAR) is preferentially induced by nerve growth factor in PC12 pheochromocytoma cells and is required for NGF-driven differentiationR Farias-Eisner, L Vician, A Silver, et al.Gynecologic Oncology|December 1, 1996
Dysgerminoma: the role of conservative surgeryA C Casey, S Bhodauria, A Shapter, et al.Gynecologic Oncology|October 1, 1994
The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgeryR Farias-Eisner, F Teng, M Oliveira, et al.Gynecologic Oncology|July 1, 1993
The etiology and management of diarrhea in the gynecologic oncology patientF D Cirisano, J S Greenspoon, R Stenson, et al.Gynecologic Oncology|April 1, 1994
Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) diseaseR Farias-Eisner, F D Cirisano, D Grouse, et al.Journal of Neuroscience Research|February 15, 2001
Expression of the urokinase plasminogen activator receptor is transiently required during "priming" of PC12 cells in nerve growth factor-directed cellular differentiationR Farias-Eisner, L Vician, S Reddy, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 9, 2002
FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survivalS Memarzadeh, C H Holschneider, R E Bristow, et al.Pageof 3